

May 6th, 2010

Santen Pharmaceutical, Co., Ltd.

Santen Launches Glaucoma and Ocular Hypertension Treatment TAFLOTAN[®] in Korea

Santen Pharmaceutical Korea Co., Ltd. (Osaka Stock Exchange : 4536, hereafter “Santen”), announced today that Santen Pharmaceutical Korea Co., Ltd.(hereafter “Santen Korea”), its wholly owned subsidiary in Korea has launched TAFLOTAN Ophthalmic Solution 0.0015%, an open angle glaucoma and ocular hypertension treatment.

TAFLOTAN Ophthalmic Solution 0.0015% (generic name: tafluprost) is a prostaglandin analogue developed in Japan for the lowering of intraocular pressure (IOP) in open angle glaucoma and ocular hypertension. The drug was co-developed by Santen and Asahi Glass Co., Ltd. (Tokyo Stock Exchange : 5201). Santen Korea has obtained marketing authorization for TAFLOTAN from the Korea Food & Drug Administration in June, 2009.

Glaucoma is a disease in which the optic nerve is damaged by IOP elevation, etc., causing progressive visual field loss, if left untreated it may lead to blindness. It is a major cause of visual disturbance (visual acuity loss, blindness) by ocular disease. Glaucomatous optic nerve damage and visual field loss is progressive and irreversible in general, early detection and early treatment of glaucoma is essential. The basic treatment for glaucoma is IOP lowering as well as IOP control.

TAFLOTAN is a prostaglandin analogue which has a distinguishable characteristic when compared to existing glaucoma treatments. Santen believes that with the launch of TAFLOTAN, it can contribute in improving the Quality of Life of patients in Korea. Santen Korea will conduct direct marketing through its own sales network thus enabling it to fully utilize the internal expertise to deliver medical information which the doctors need.

TAFLOTAN is currently being marketed in 15 countries and regions world wide (including Korea). Korea will be the third country in Asia whereby Santen has launched tafluprost after Japan and Hong Kong, In Japan, Santen has been selling TAPROS Ophthalmic Solution 0.0015% since December 2008.

About Tafluprost

Product Name:	TAFLOTAN Ophthalmic Solution 0.0015%
Generic Name:	Tafluprost
Dosage form:	Aqueous Ophthalmic Solution
Indication:	Open Angle Glaucoma and Ocular Hypertension
Dosage:	1 Drop/Time, Once Daily
Storage method:	Can be stored at room temperature

Contact Information:

Takashi Hibi
Corporate Communication Group
Santen Pharmaceutical, Co., Ltd.
3-9-19 Shimoshinjo, Higashiyodogawa-ku,
Osaka 533-8651 Japan
TEL : +81-6-6321-9957